Established in 2016, this annual gathering brings together Biotech CEOs from across Europe to discuss issues of concern to them as leaders of companies they want to position for growth and success.
Who Participates
Biotech CEO Summits are limited to CEOs focused on leading their organizations through the ever-evolving biotech landscape, transforming individual companies and the industry as a whole. Non-CEO participants include a select group of industry leaders.
About the Program
The program includes fireside chats, case studies and group discussions that address a range of global issues key to biotech CEOs and their companies. The Summit format facilitates engagement, discussion and interaction with and between all CEOs. The topics are identified in consultation with the advisory board, and include discussions on strategy (asset selection, collaborations, market approach), financing (public and private), communications to all audiences (shareholders, investors, board of directors, patients, regulatory bodies, and team), human resources (board and team development and management), and lessons learned during make or break situations.
Participant Benefits
An important benefit of participating in the Summit is the development of relationships between CEOs and the select group of other industry thought leaders. The program is designed to ensure all CEOs spend quality time together. Everyone is encouraged to participate in the candid discussions, to share their experiences and to ask questions. All CEOs are invited to suggest topics for discussion. Throughout the Summit, networking sessions, dinners and activities provide opportunities for CEOs to meet one-on-one and build relationships.
Companies Represented By Their CEOs at Past EU and US Summits
| 4SC AG Abdera Therapeutics ABIVAX Ablynx Abzena PLC Achilles Therapeutics Actimed Therapeutics Acucela Adjuvance Technologies Aelin Therapeutics Aimmune Therapeutics Akari Therapeutics Albireo Pharma Amplyx Pharmaceuticals Anake Therapeutics Anocca Apaxen Apexigen Apogenix AG Aqilion Arcturus Therapeutics Arecor Arima Genomics Aristea Therapeutics ARMO Biosciences Inc Artelo Biosciences, Inc. Artidis Asher Biotherapeutics Ashvattha Therapeutics Aspen Biosciences, Inc. Assembly Biosciences AtG Therapeutics Atomwise, Inc. AUM Biosciences Aura Biosciences Autifony Therapeutics AVEO Oncology AzurRx BioPharma BC Platforms Binx Health Bioasis Technologies Inc. BioAtla BioInvent International bioLytical Laboratories Biophytis Blade Therapeutics BliNK Biomedical SAS BRAINCURES Brinter, Inc. Cadrenal Therapeutics Caliber BioSciences Calithera Biosciences Calliditas Therapeutics Cancer Prevention Pharmaceuticals, Inc. Cantargia Cardior Pharmaceuticals Carmell Therapeutics CatalYm GmbH Cellaion CellFE Celltheon ChemoCentryx Cold Genesys, Inc. Conatus Pharmaceuticals Concert Pharmaceuticals Context Therapeutics Crescendo Biologics CureVac N.V. Curve Therapeutics CXL Ophthalmics Cytovia Therapeutics Daré Bioscience DelMar Pharmaceuticals Dicerna Pharmaceuticals Drawbridge Health Earli Eden BioPharma Elex Biotech, Inc. Eloxx Pharmaceuticals EOLO USA INC Epics Therapeutics Epilepsygtx Limited e-Therapeutics Ethicann Pharmaceuticals Ethris GmbH |
Evotec AG |
Orpheris, Inc. |
Organizers
Demy-Colton produces highly specialized, targeted investor and business development conferences exclusively for the biopharmaceutical and life sciences industry. With a proven track record and deep domain knowledge, we develop programs that add value and routinely exceed the expectations of our participants.
